Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects

Bringing technology to market: National Heart, Lung, and Blood Institute SBIR Phase IIB projects

Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute....

Full description

Saved in:
Bibliographic Details
Published in:Science & public policy Vol. 51; no. 1; pp. 144 - 148
Main Authors: Nienow, Sara, Leonchuk, Olena, O’Connor, Alan C, Link, Albert N
Format: Journal Article
Language:English
Published: UK Oxford University Press 29-01-2024
Subjects:
NHLBI
H51
O38
Phase IIB projects
H11
SBIR program
technology commercialization
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The National Heart, Lung, and Blood Institute (NHLBI) is the fourth largest institute in the US National Institutes of Health (NIH). Surprisingly, there is a conspicuous void of policy studies related to the research activities of NHLBI in comparison to NIH or the National Cancer Institute. This paper investigates the likelihood that a business funded through NHLBI’s Small Business Innovation Research (SBIR) program will commercialize from its Phase IIB translational support. Commercialization is one performance metric that quantifies a policy dimension of the success of the funded SBIR project. Based on an empirical analysis of sixty-one Phase IIB projects, we find that the most significant covariate with the likelihood of commercialization is the growth in human capital within the business since the Phase IIB award.
ISSN:0302-3427
1471-5430
DOI:10.1093/scipol/scad063